Buying a GLP-1 in India: What Actually Proves a Pack Is Genuine

If a GLP-1 medicine has been offered to you through a route you are unsure about, the question is not how convincing the box looks. Falsified packs are manufactured to look convincing. That is the entire point of them.

The useful question is what the supply route left behind, because a lawful one leaves a trail that ties a named patient to a named batch from a named manufacturer, and an unlawful one leaves nothing. What follows is what that trail consists of, what has genuinely been found falsified and where, what each authenticity check does and does not prove, and what to do with a pack you have doubts about.

Key Takeaways:

• GLP-1 medicines are Schedule H under the Drugs Rules 1945. Lawful retail requires a registered practitioner's prescription and dispensing by or under a registered pharmacist. Both conditions are cumulative, and neither one alone makes a sale compliant.
• The WHO's June 2024 alert on falsified semaglutide batches covers findings in Brazil, the UK and the US. No Indian detection of those three specific batches has been located as of September 2026.
• India's documented GLP-1 counterfeiting case (Haryana, April 2026) involved product presented as tirzepatide, a different molecule from those in the WHO alert.
• A QR code scan validates encoded information. It does not establish contents, sterility or whether cold chain was maintained.
• Personal import under Rule 36 requires a permit applied for before the medicine arrives, not produced afterwards. Small quantity and personal use do not automatically make a purchase lawful.

GLP-1 receptor agonists are Schedule H medicines under the Drugs Rules, 1945. Rule 65 prohibits retail sale except on a registered medical practitioner's prescription, dispensed by or under the personal supervision of a registered pharmacist. Those two conditions are cumulative, and neither one alone makes a sale compliant.

Some Indian marketing authorisations add a further condition, restricting prescribing to particular specialties for particular indications. That is a question about who may lawfully prescribe rather than about the paperwork in front of you. A video consultation does not change any of this: telemedicine does not convert a prescription-only medicine into an over-the-counter one, and the conditions under which a remote prescription is valid.

What matters here is the record, because the record is the only part of the transaction that survives it. A Schedule H dispensing entry has to capture the prescriber and the patient, the medicine and the quantity, and the manufacturer, batch number and expiry. Cash or credit memos are retained for three years, while other Rule 65 records ordinarily remain available for at least two. A prescription cannot be reused unless the prescriber has expressly permitted repeat dispensing.

Those requirements are not administrative decoration. Because the entry ties a named patient to a named batch from a named manufacturer, a pack that later appears in a regulator's alert can be traced back to the people who received it. A pack with no such entry anywhere cannot.

The packaging is what a counterfeiter controls, and the dispensing record is what they cannot create. That is the practical difference between a supply route that can be audited after the fact and one that disappears the moment a question is asked of it.

There is a second reason a legitimate supply route is quiet. Indian rules restrict how these medicines may be promoted to the public at all, so an entity marketing a named weight-loss injection to you is, by that act alone, telling you something about itself.

International coverage and the Indian position get spliced together, usually wrongly. They are separate events involving separate molecules in separate countries.

Each alert involves a different molecule, country and finding:

• WHO Medical Product Alert No. 2/2024 (19 June 2024): Semaglutide. Detected in Brazil and the UK (October 2023) and the US (December 2023). Three falsified batches identified: LP6F832, NAR0074 paired with serial 430834149057, and MP5E511. No Indian detection of these batches has been located.
• Haryana seizure (April 2026): Product presented as tirzepatide. Detected in India. The manufacturer confirmed the products were not its own and did not come from its authorised chain. Laboratory analysis of the contents was pending at time of reporting.
• Interpol alert (July 2026): Semaglutide, batch FJ3178. Detected in Austria. Prompted Indian supply-chain surveillance. Did not by itself establish that the batch had been found in India.

The WHO alert deserves a specific note. In the MP5E511 case, the batch number itself was genuine and the product bearing it was not. An identifier can be real and the contents still falsified.

India's own documented GLP-1 counterfeit case involved a different molecule. Describing it as an Indian detection of WHO's falsified semaglutide batches would be wrong on the country, wrong on the drug and wrong on the alert. As of September 2026, no Indian detection of those three semaglutide batches has been located, and no primary dataset establishes the nationwide scale of India's GLP-1 grey market.

What does exist is enforcement activity, and it indicates what regulators found when they went looking. A nationwide drive in 2026 covered 49 online-pharmacy warehouses, wholesalers, retailers and slimming or wellness clinics, with notices issued over unauthorised distribution, non-compliant dispensing and misuse.

A separate state-level drive in Telangana in August inspected 43 medical shops and reported sales without the required prescriptions, missing bills and records, and dispensing without a registered pharmacist on the premises. One caveat belongs with those figures: the primary CDSCO documents could not be retrieved from the regulator's publicly indexed notice pages. Their contents are documented through an official parliamentary answer and trade reporting rather than through the primary text.

Two different kinds of evidence therefore circulate about the Indian market, and they carry different weight. A seizure, an inspection notice or a regulator's alert is a finding by an authority with the power to test and to act on the result. A report that a practice is common is evidence that the practice has been observed and written about. The inspection drives indicate which irregularities were found. Neither establishes what proportion of Indian GLP-1 supply is affected.

A verification step that proves less than the person performing it assumes is worse than no check at all, because it converts uncertainty into false confidence. Each of the checks below is worth doing, and each has a stated ceiling.

What each check establishes, and where it stops:

• An itemised invoice from a licensed pharmacy, dispensed by a registered pharmacist: Establishes that the sale was recorded, attributable and traceable back through the chain. Does not establish anything about the contents of the pack.
• The label carrying drug name and strength, manufacturer, batch number, expiry dates, Schedule H warning and storage instructions: Establishes that the pack carries what Indian labelling rules require. Does not establish that the pack was filled by the manufacturer named on it.
• Scanning a barcode or QR code (India mandates these for the notified top 300 brands under Schedule H2, not for every medicine): Establishes that the encoded information resolves and matches the printed detail. Does not establish contents, sterility, or whether cold chain was maintained.
• Checking identifiers with the manufacturer, using contact details obtained independently from its official Indian website: Establishes that the manufacturer recognises the batch and serial as its own. Does not establish that the physical pack in front of you is the one it recognises.
• Searching CDSCO's monthly not-of-standard-quality and spurious-drug alerts by product and batch: Establishes whether a specific tested batch has been flagged. Does not establish anything about untested batches of the same product. An alert attaches to the tested batch, not automatically to every product containing that molecule.

The alerts in that last point deserve a note. CDSCO publishes not-of-standard-quality lists monthly, and they record samples that failed testing during routine surveillance, a narrower finding than a spurious-drug declaration. A batch appearing in one of those lists says something specific about that batch. It says nothing about other batches of the same product, and the absence of a batch from the list says only that it has not been tested and failed.

Contact details matter more than they sound. Taking them from the pack, a message or a listing defeats the purpose, because those are exactly the surfaces a falsified supply controls. CDSCO's own spurious drugs guidance sets out the identification and verification route in more detail.

Bringing an unregistered medicine into India for personal use is possible, and it is a permit process rather than a purchase. CDSCO operates the Form 12A and Form 12B route under Rule 36, which requires a prescription and a permit and limits a single medicine to 100 average doses.

The permit is applied for before the medicine arrives, not produced afterwards to explain it. The quantity ceiling is also easy to misread: the limit applies to a single medicine, and it is the permit rather than the invoice that establishes the import was lawful.

The corollary is the part that gets ignored. An overseas purchase or a courier shipment is not made lawful merely by being intended for personal use, and the absence of a permit is not a technicality that resolves itself at customs. A product that arrives outside that route also arrives outside every traceability mechanism described above: no Indian dispensing record, no invoice from a licensed pharmacy, no state drug controller with jurisdiction over the seller, and no practical path to establishing whether cold chain held across the journey.

Do not use it. A suspect pack is worth more as evidence than as medicine. Keep the pack, the invoice and whatever is known about how it was stored. Then notify the manufacturer through independently obtained contact details and the State Drug Controller with jurisdiction. Any adverse reaction can also be reported through the Pharmacovigilance Programme of India helpline on 1800-180-3024, which is a separate route from a complaint about the product's authenticity and worth using alongside it.

Two limits are worth stating plainly. No universal Indian serial-number checker covers every GLP-1 pack, and no amount of packaging or QR inspection can conclusively establish chemical identity or quality. That requires laboratory analysis, which is why regulators test batches rather than eyeball them.

Everything on this page concerns provenance, which is a different question from whether one of these medicines is clinically appropriate for you at all. That question sits in our GLP-1 side effects overview. Where provenance checks out and you still want certainty about the device in your hand, checking a pen against the features its manufacturer describes is a separate exercise from checking the paperwork around it.

Want to start a GLP-1 through a route where the supply chain is traceable and the prescription is issued by a registered clinician? Book a consultation with a Voy clinician.

This article is for general information and education only and is not medical advice, diagnosis, or treatment. GLP-1 and other medications referenced are prescription-only and are appropriate only for certain people under the supervision of a qualified clinician. Do not start, stop, or change any medication based on this article. Please consult a registered medical practitioner about your individual circumstances. Information reflects what was available at the time of review and may change.